Male sex and the pattern of recurrent myeloid mutations are strong independent predictors of blood transfusion intensity in patients with myelodysplastic syndromes

Jenny Rydén^{1

2}, Gustaf Edgren^{3

4}, Mohsen Karimi¹, Gunilla Walldin¹, Magnus Tobiasson^{1

2}, Agneta Wikman^{5

6}, Eva Hellström-Lindberg^{1

2}, Petter Höglund^{7

8}

Affiliations

¹ Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
² Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
³ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
⁴ Department of Cardiology, Södersjukhuset, Stockholm, Sweden.
⁵ Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
⁶ Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden.
⁷ Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Petter.Hoglund@ki.se.
⁸ Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. Petter.Hoglund@ki.se.

Jenny Rydén et al. Leukemia. 2019 Feb.

. 2019 Feb;33(2):522-527.

doi: 10.1038/s41375-018-0256-0. Epub 2018 Sep 28.

Jenny Rydén^{1

2}, Gustaf Edgren^{3

4}, Mohsen Karimi¹, Gunilla Walldin¹, Magnus Tobiasson^{1

2}, Agneta Wikman^{5

6}, Eva Hellström-Lindberg^{1

2}, Petter Höglund^{7

8}

¹ Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
² Hematology Center, Karolinska University Hospital, Stockholm, Sweden.
³ Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
⁴ Department of Cardiology, Södersjukhuset, Stockholm, Sweden.
⁵ Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden.
⁶ Department of Laboratory Medicine, Karolinska University Hospital, Stockholm, Sweden.
⁷ Center for Hematology and Regenerative Medicine, Department of Medicine, Karolinska Institutet, Stockholm, Sweden. Petter.Hoglund@ki.se.
⁸ Department of Clinical Immunology and Transfusion Medicine, Karolinska University Hospital, Stockholm, Sweden. Petter.Hoglund@ki.se.

No abstract available

References

1. Cazzola M, Malcovati L. Myelodysplastic syndromes--coping with ineffective hematopoiesis. N Eng J Med. 2005;352:536–8. - DOI
1. Zhao J, Ryden J, Wikman A, Norda R, Stanworth SJ, Hjalgrim H. et al. Blood use in hematologic malignancies: a nationwide overview in Sweden between 2000 and 2010. Transfusion. 2018;58:390–401. - DOI
1. Ramsey SD, McCune JS, Blough DK, McDermott CL, Beck SJ, Lopez JA, et al. Patterns of blood product use among patients with myelodysplastic syndrome. Vox Sang. 2012;102:331–7. - DOI
1. Platzbecker U, Hofbauer LC, Ehninger G, Holig K. The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes. Leuk Res. 2012;36:525–36. - DOI
1. de Swart L, Smith A, Johnston TW, Haase D, Droste J, Fenaux P, et al. Validation of the revised international prognostic scoring system (IPSS-R) in patients with lower-risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet MDS (EUMDS) registry. Br J Haematol. 2015;170:372–83. - DOI